Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 1 11Phase 1/2 5Phase 3 3Phase EARLY_PHASE1 2Phase 4 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Dermatologic 1

Conditions

Solid Tumors 1Melanoma 1

Interventions

Dexamethasone 13Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Lenalidomide 7Fluorouracil 7pembrolizumab 6Rituximab 6Prednisone 6Letrozole 6Cisplatin 6Carboplatin 6Propofol 5Human Papillomavirus Recombinant Vaccine nonavalent 5trametinib 4lenvatinib 4dabrafenib 4cabozantinib 4anlotinib 4Trastuzumab 4Tamoxifen 4Standard of Care 4Sodium Chloride 4Ropivacaine 4Paclitaxel 4Immune Checkpoint Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × binimetinib × 1 year × Clear all
NCT07092410 2026-04-21

SuRage-EB

SRH Wald-Klinikum Gera GmbH

Phase 4 Withdrawn
Dermatologic

Melanoma

NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Pfizer

Phase 4 Recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡